CoChat
Sign Up
Cited by 661Pharmaceutical Economics and PolicyHealthcare Systems and ReformsPharmaceutical Quality and Counterfeiting

Essential medicines for universal health coverage

Open access
Wirtz, Veronika J, Hogerzeil, Hans V, Gray, Andrew L, Bigdeli, Maryam, de Joncheere, Cornelis P, Ewen, Margaret A, Gyansa-Lutterodt, Martha, Jing, Sun +14 more·2017·The Lancet
DOI 10.1016/s0140-6736(16)31599-9PMC PMC7159295
Open this paper in CoChat — free accountOpen PDF

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(16)31599-9

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 220 · Cited by 661

Research works printed but not linked: 31

  1. [39]King M Medical care in developing countries 1966 Oxford University Press Nairobi
  2. [40]Van Amelsvoort V Standard notes for Tanzanian dispensaries (experimental edition) 1970 Dar es Salaam University, Department of Preventive and Social Medicine Dar es Salaam
  3. [44]WHO The rational use of drugs. Report of the conference of experts: Nairobi, 25-29 November 1985 http://apps.who.int/medicinedocs/documents/s17054e/s17054e.pdf (accessed April 10, 2016).
  4. [95]The Lancet Zika virus resource centre http://www.thelancet.com/campaigns/zika (accessed July 30, 2016).
  5. [103]WHO World health report. Health systems financing: the path to universal health coverage 2010 World Health Organization Geneva PMC2878164 20539847
  6. [117]Baruwa E Islam M Literature review of costing supply chains and logistics 2008 Abt Associates for the USAID, Deliver Project Washington, DC
  7. [119]The Global Fund and PEPFAR. The Global Fund-PEPFAR ARV Supplier Conference. Dubai, United Arab Emirates; June 24–25, 2014.
  8. [145]WHO/Health Action International Review series on pharmaceutical pricing policies and interventions. Working Paper 1: External reference pricing http://haiweb.org/wp-content/uploads/2015/08/ERP-final-May2011a1.pdf 2011 (accessed Oct 1, 2016).
  9. [146]WHO/Health Action International Review series on pharmaceutical pricing policies and interventions. Working Paper 3: The regulation of mark-ups in the pharmaceutical supply chain http://haiweb.org/medicineprices/05062011/Mark-ups%20final%20May2011.pdf 2011 (accessed Oct 1, 2016).
  10. [147]WHO/Health Action International Review series on pharmaceutical pricing policies and interventions. Working Paper 5: Sales taxes on medicines http://haiweb.org/wp-content/uploads/2015/08/Taxes-final-May2011a1.pdf 2011 (accessed Oct 1, 2016).
  11. [150]World Health Organization/Health Action International Review series on pharmaceutical pricing policies and interventions. Working Paper 2: The role of health insurance in the cost-effective use of medicines http://haiweb.org/wp-content/uploads/2015/08/2_WHOHAI_Policy-Brief_Insurance_2015.pdf 2011 (accessed Oct 1, 2016).
  12. [174]Kaplan WA Local production and access to medicines in low- and middle-income countries. A literature review and critical analysis 2011 World Health Organization Geneva
  13. [188]International Network of Agencies for Health Technology Assessment (INAHTA) INAHTA member list http://www.inahta.org/members/ (accessed July 24, 2016). PMC11811950 39895096
  14. [197]Whyte P Hall C The Role of Health Technology Assessment in Medicine Pricing and Reimbursement. HAI/WHO. Review Series on Pharmaceutical Pricing Policies and Interventions. Working Paper 6. WHO/HAI Project on Medicine Prices and Availability www.haiweb.org/wp-content/uploads/2015/08/HTA-final-Aug2013a1.pdf June 2013 (accessed April 9, 2016).
  15. [222]Institute of Medicine Gostin LO Buckley GJ Countering the problem of falsified and substandard drugs 2013 The National Academies Press Washington, DC 24872973
  16. [235]WHO International Conference of Drug Regulatory Authorities (ICDRA) http://www.who.int/medicines/icdra (accessed Feb 26, 2016).
  17. [291]Management Sciences for Health Managing for rational medicine use. Chapter 27. In: Managing access to medicines and health technologies 2012 Management Sciences for Health Arlington, VA
  18. [310]Effective Practice and Organisation of Care (EPOC) What study designs should be included in an EPOC review? EPOC Resources for review authors http://epoc.cochrane.org/sites/epoc.cochrane.org/files/uploads/05%20What%20study%20designs%20should%20be%20included%20in%20an%20EPOC%20review%202013%2008%2012_2.pdf 2013 (accessed Jan 24, 2016).
  19. [312]Rowe A Rowe S Peters D Holloway K Chalker J Ross-Degnan D Health care provider performance review [presentation for the Institute of Medicine] https://iom.nationalacademies.org/∼/media/Files/Activity%20Files/Global/USAIDstandingcomm/Jan%2028-29/8%20Rowe.pdf Jan 27, 2015 (accessed April 10, 2016).
  20. [313]Effective Practice and Organisation of Care (EPOC) Suggested risk of bias criteria for EPOC reviews. EPOC Resources for review authors 2015 Norwegian Knowledge Centre for the Health Services Oslo
  21. [347]Medicines Transparency Alliance A review of the pilot http://www.medicinestransparency.org/fileadmin/uploads/Documents/MeTA_review_pilot.pdf (accessed Oct 1, 2016).
  22. [371]Année du medicament Rev Prescrire 35 (376):132-136, 2015. English summary available online http://english.prescrire.org/en/109B561E03CAD2313B7046521B310752/Download.aspx (accessed April 10, 2016).
  23. [377]Gaffney A Mezher M Regulatory explainer: everything you need to know about FDA's priority review vouchers. July 2, 2015, updated March 2, 2016 http://www.raps.org/Regulatory-Focus/News/2015/07/02/21722/Regulatory-Explainer-Everything-You-Need-to-Know-About-FDA%E2%80%99s-Priority-Review-Vouchers/ (accessed April 10, 2016).
  24. [394]Médecins Sans Frontières Health groups ask senate for changes to FDA priority review voucher program for neglected diseases http://www.doctorswithoutborders.org/article/health-groups-ask-senate-changes-fda-priority-review-voucher-program-neglected-diseases Nov 19, 2015 (accessed Feb 28, 2016).
  25. [412]Boulet P 't Hoen E Procurement of patented medicines by SADC Member States: a report for SADC Member States and the future SADC Pharmaceutical Procurement Services (SPPS) based on the lessons learned during the Trade, TRIPS and Access to Medicines project 2012–2014 https://www.researchgate.net/publication/286925982_Procurement_of_Patented_Medicines_by_SADC_Member_States (accessed March 3, 2016).
  26. [418]van Onselen L TPP IP chapter “a disaster for global health” http://www.macrobusiness.com.au/2015/10/tpp-ip-chapter-a-disaster-for-global-health/ (accessed Feb 28, 2016).
  27. [429]Jennings G Emerging infection diseases: global risks, global strategy. A global village http://www.aglobalvillage.org/journal/issue5/the-right-to-health/emerging-infectious-disease/ Oct 5, 2011 (accessed Feb 28, 2016).
  28. [458]IDRI IDRI and Sanofi Pasteur team with philanthropy to develop new model for vaccine development http://idri.org/press-10-15-15.php Oct 15, 2015 (accessed July 6, 2016).
  29. [459]GSK GSK expands graduated approach to patents and intellectual property to widen access to medicines in the world's poorest countries http://www.gsk.com/en-gb/media/press-releases/2016/gsk-expands-graduated-approach-to-patents-and-intellectual-property-to-widen-access-to-medicines-in-the-world-s-poorest-countries/ March 31, 2016 (accessed April 1, 2016).
  30. [477]Organization for Economic Corporation and Development Pharmaceutical spending trends and future challenges [chapter 2]. Health at Glance 2015 2015 OECD Paris
  31. [481]WHO 14th International Conference of Drug Regulatory Authorities 2010 World Health Organization Geneva

Authors
Wirtz, V. J., Hogerzeil, H. V., Gray, A. L., Bigdeli, M., de Joncheere, C. P., Ewen, M. A., Gyansa-Lutterodt, M., Jing, S., Luiza, V. L., Mbindyo, R. M., Möller, H., Moucheraud, C., Pécoul, B., Rägo, L., Rashidian, A., Ross-Degnan, D., Stephens, P. N., Teerawattananon, Y., 't Hoen, E. F. M., Wagner, A. K., Yadav, P., & Reich, M. R.
Affiliations
  • Boston University (US)
  • University Medical Center Groningen (NL)
  • University of KwaZulu-Natal (ZA)
  • World Health Organization (CH)
  • Health Action International (NL)
  • Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
  • Escola Nacional de Saúde Pública Sergio Arouca (BR)
  • United Nations Children's Fund (US)
  • University of California, Los Angeles (US)
  • Drugs for Neglected Diseases Initiative (CH)
  • World Health Organization - Egypt (EG)
  • IQVIA (United States) (US)
  • Ministry of Public Health (TH)
  • Harvard University (US)
  • University of Michigan (US)
Corresponding author
Wirtz, Veronika J
ORCID
Venue
The Lancet
Publisher
Elsevier BV
Published
2017-01
Volume
389
Issue
10067
Pages
403-476
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
DOI
10.1016/s0140-6736(16)31599-9
PMC
PMC7159295
OpenAlex
W2554416008
Cited by
661
References
220
Citations by year
2026: 78 · 2025: 88 · 2024: 47 · 2023: 64 · 2022: 70 · 2021: 72 · 2020: 82 · 2019: 61 · 2018: 57 · 2017: 34 · 2016: 7
FWCI
16.25
Type
journal article
Language
en
Open access
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
Funders
  • Bill and Melinda Gates Foundation
  • World Health Organization
  • Wellcome Trust
Topics
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
  • Social Sciences › Economics, Econometrics and Finance › Finance › Healthcare Systems and Reforms
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pharmaceutical Quality and Counterfeiting
Keywords
essential medicines, universal health coverage, medicines policy, right to health, health equity, Sustainable Development Goal 3, health system performance, pharmaceutical industry, data sharing, accountability
MeSH terms
Conservation of Natural Resources, Developing Countries, Health Expenditures, Humans, World Health Organization, Drug Costs, Drugs, Essential, Universal Health Insurance

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review